Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 21151 AL 21165

Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases

Konovalova J, Gerasymchuk D, Parkkinen I, Chmielarz P, Domanskyi A.

Int J Mol Sci. 2019 Nov 30;20(23):6055. doi: 10.3390/ijms20236055.

Zinc transporters in Alzheimer's disease

Xu Y, Xiao G, Liu L, Lang M.

Mol Brain. 2019 Dec 9;12(1):106. doi: 10.1186/s13041-019-0528-2.

Fornical Closed-Loop Stimulation for Alzheimer's Disease

Senova S, Chaillet A, Lozano AM.

Trends Neurosci. 2018 Jul;41(7):418-428. doi: 10.1016/j.tins.2018.03.015. Epub 2018 May 4.

Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

Trompetero A, Gordillo A, Del Pilar MC, Cristina VM, Bustos Cruz RH.

Curr Pharm Des. 2018;24(1):22-45. doi: 10.2174/1381612823666170828133059.

Common molecular pathogenesis of disease-related intrinsically disordered proteins revealed by NMR analysis

Shigemitsu Y, Hiroaki H.

J Biochem. 2018 Jan 1;163(1):11-18. doi: 10.1093/jb/mvx056.

A refined concept: α-synuclein dysregulation disease

Mochizuki H, Choong CJ, Masliah E.

Neurochem Int. 2018 Oct;119:84-96. doi: 10.1016/j.neuint.2017.12.011. Epub 2018 Jan 2.

Neuropathology correlates of cognitive assessments

Brett FM, Kearney H.

Ir J Med Sci. 2018 Aug;187(3):835-844. doi: 10.1007/s11845-017-1733-6. Epub 2018 Jan 18.

Bottom-up gamma maintenance in various disorders

Garcia-Rill E, Mahaffey S, Hyde JR, Urbano FJ.

Neurobiol Dis. 2019 Aug;128:31-39. doi: 10.1016/j.nbd.2018.01.010. Epub 2018 Jan 17.

Mutation Screening of the CHCHD2 Gene for Alzheimer's Disease and Frontotemporal Dementia in Chinese Mainland Population

Che XQ, Zhao QH, Huang Y, Li X, Ren RJ, Chen SD, Guo QH, Wang G.

J Alzheimers Dis. 2018;61(4):1283-1288. doi: 10.3233/JAD-170692.

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

Hölscher C.

Neuropharmacology. 2018 Jul 1;136(Pt B):251-259. doi: 10.1016/j.neuropharm.2018.01.040. Epub 2018 Jan 31.

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, Youakim JM, Owen R, Stankovic S; ADP Investigators.

Lancet Neurol. 2018 Mar;17(3):213-222. doi: 10.1016/S1474-4422(18)30039-5.

Shedding light on aberrant interactions - a review of modern tools for studying protein aggregates

Kundel F, Tosatto L, Whiten DR, Wirthensohn DC, Horrocks MH, Klenerman D.

FEBS J. 2018 Oct;285(19):3604-3630. doi: 10.1111/febs.14409. Epub 2018 Mar 4.

Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives

Baker DJ, Petersen RC.

J Clin Invest. 2018 Apr 2;128(4):1208-1216. doi: 10.1172/JCI95145. Epub 2018 Feb 19.

Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers

Tonda-Turo C, Origlia N, Mattu C, Accorroni A, Chiono V.

Curr Med Chem. 2018;25(41):5755-5771. doi: 10.2174/0929867325666180221125759.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias